Business Wire

CA-WILSON-SONSINI

9.11.2022 14:01:38 CET | Business Wire | Press release

Share
Jindrich Kloub Joins Wilson Sonsini’s Antitrust and Competition Team in Brussels

Wilson Sonsini Goodrich & Rosati, the premier provider of legal services to technology, life sciences, and growth enterprises worldwide, announced today that Jindrich Kloub has joined the firm’s antitrust and competition department as a partner in the Brussels office. Kloub’s more than 10 years of service at the European Commission’s Directorate-General for Competition and his most recent Hong Kong Competition Commission (HKCC) role illustrate the range of his enforcement agency experience and connections. His addition fortifies Wilson Sonsini’s acclaimed antitrust and competition practice in the United States and Europe.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221109005164/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Jindrich Kloub, Partner, Wilson Sonsini (Photo: Business Wire)

Most recently, Kloub was executive director of operations at the HKCC, where he was responsible for all antitrust enforcement since 2017. In this role, he oversaw numerous precedent-setting investigations, including one that led to the HKCC’s first abuse of dominance enforcement action, as well as its first enforcement outcomes involving resale price maintenance, digital markets, leniency, settlements, commitments, director disqualifications and compliance remedies.

Kloub also has substantial international antitrust and competition policy experience. For example, in addition to leading the development of a fining methodology and cooperation and commitments policies, he oversaw major revisions to the HKCC’s leniency guidelines, which have been described within the private antitrust and competition bar as a world-class policy.

Before joining the HKCC, Kloub worked as an attorney at the European Commission’s Directorate-General for Competition (DG COMP) for more than a decade. During that time, he conducted numerous international cartel investigations, including major international cartel investigations in the financial services sector involving LIBOR and Forex benchmark rates.

“Because Hong Kong’s competition law was based on EU competition law, Jindrich has worked at two enforcement agencies that are highly engaged in monitoring and enforcing competition and antitrust laws of importance to our clients,” said Doug Clark, managing partner, Wilson Sonsini. “Jindrich’s enforcement and policy experience is the ideal combination to complement our already highly regarded antitrust and competition practice. We’re very excited to welcome him to the firm.”

Kloub’s addition comes just over a year and a half after Wilson Sonsini announced that Brent Snyder was joining the firm’s antitrust and competition practice on March 1, 2021. Snyder also joined the firm from the HKCC, having served as its CEO from 2017 through 2020.

“I’m pleased to be joining Wilson Sonsini’s accomplished competition and antitrust team, and excited about my role in helping the firm continue to expand its impressive, global practice and presence in Europe,” said Kloub. “This position not only gives me a chance to apply my enforcement and policy experience to help clients manage matters in both Europe and the U.S., but it’s also an exciting opportunity to work with Wilson Sonsini’s impressive range of clients.”

“Jindrich’s addition to our Brussels office further demonstrates Wilson Sonsini’s growing presence and strong brand in Europe – especially within the complex and constantly changing digital regulatory framework that impacts both antitrust and data protection,” said Cedric Burton, managing partner of Wilson Sonsini’s Brussels office. “Our growing team will be able to offer a new level of service and expertise on the ground to our clients within the European Union.”

Kloub earned his Master of Laws from Charles University School of Law in Prague in 2003 and his LL.M. from Columbia Law School in 2009. He has served as a visiting professor of competition law at Lille’s Catholic University for more than a decade, spoken widely at international conferences, and written numerous articles on competition law.

About Wilson Sonsini Goodrich & Rosati

For more than 60 years, Wilson Sonsini’s services and legal disciplines have focused on serving the principal challenges faced by the management and boards of directors of business enterprises. The firm is nationally recognized as a leading provider to growing and established clients seeking legal counsel to complete sophisticated corporate and technology transactions; manage governance and enterprise-scale matters; assist with intellectual property development, protection, and IP-driven transactions; represent them in contested disputes; and/or advise them on antitrust or other regulatory matters. With deep roots in Silicon Valley, Wilson Sonsini has 19 offices in technology and business hubs worldwide. For more information, please visit www.wsgr.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005164/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release

–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release

Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release

MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye